Key result
A detailed procedure for a three-plasmid transfection method for rAAV production, purification, and a PCR-based strategy to discover novel AAV capsid sequences is described.
Provides a detailed methodological protocol for the production, purification, quality control, and discovery of recombinant adeno-associated viral vectors for clinical gene therapy.
Supports lab-scale rAAV production for gene therapy; leaves open the need for clinical validation before therapeutic use.
In this unit, we describe the detailed procedure for a three-plasmid transfection method for rAAV production, and discuss its advantages, limitations, and troubleshooting techniques. We further discuss the rAAV purification process using CsCl gradients, as well as subsequent quality control methods using SDS-PAGE and real-time PCR to assess vector purity, packaging efficiency, and viral titer. Finally, we elaborate on a PCR-based strategy that can be used to discover novel AAV capsid sequences from primate tissue, which can be used to develop newer-generation rAAVs with a greater diversity of tissue tropism for clinical gene therapy.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2012) studied this question. A detailed procedure for a three-plasmid transfection method for rAAV production, purification, and a PCR-based strategy to discover novel AAV capsid sequences is described.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: